LEXINGTON, Mass.--(BUSINESS WIRE)--Predictive Biosciences, an emerging venture developing diagnostic products for informed cancer management™, announced today the formation of a six member Scientific Advisory Board (SAB). Predictive Biosciences is commercializing a portfolio of urinary protein biomarkers for precise, real-time cancer management, with a focus on cancer survivors. The company intends to develop patient-friendly, urine-based diagnostics across multiple epithelial cancers, initially in bladder cancer.
